HOLLISTON, Mass., Dec. 6, 2016 /PRNewswire/ -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that Jim McGorry, CEO of Biostage, will participate presentation and panel discussion at the 2016 World Stem Cell Summit and RegMed Capital Conference on Wednesday, December 7th at 2:00 PM ET, being held at the Palm Beach County Convention Center, West Palm Beach, Florida.

BSTG Logo

Mr. McGorry will provide an overview of the Company and outline Biostage's expected upcoming near-term corporate, clinical and regulatory milestones that will enable the Company's transition to a clinical-stage company in 2017.

As part of his presentation, Mr. McGorry will discuss the Company's lead product candidate, the Cellspan™ Esophageal Implant, which recently received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). The Cellspan Esophageal Implant is designed to restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury or congenital abnormalities.

About Regenerative Medicine Foundation
The World Stem Cell Summit is a project of the nonprofit Regenerative Medicine Foundation. Since 2003, Regenerative Medicine Foundation and its predecessor Genetics Policy Institute have built the strongest, most comprehensive and trusted global network of Regenerative Medicine stakeholders, uniting the world's leading researchers, medical centers, universities, labs, businesses, funders, policymakers, experts in law, regulation and ethics, medical philanthropies and patient organizations. Our mission is to accelerate regenerative medicine to improve health and deliver cures. We are committed to the ethical advancement of innovative medicine powered by regenerative, restorative, and curative technologies. Learn more at  www.regmedfoundation.org.

About 2016 WSCS
The World Stem Cell Summit, is the original, translation-focused global meeting of stakeholders, now celebrating its 12th year. The 2016 WSCS is co-sponsored by the The Mayo Clinic Center for Regenerative Medicine and is organized by the Center for the Advancement of Science in Space (CASIS), the sole manager of the International Space Station U.S. National Laboratory; Centre For Commercialization Of Regenerative Medicine (Canada); Diabetes Research Institute Foundation; Kyoto University Institute for Integrated Cell Material Science; Mayo Clinic; NOVA Southeastern University Cell Therapy Institute; The Cure Alliance; University of Miami Miller School of Medicine ISCI (Interdisciplinary Stem Cell Institute); and Wake Forest School of Medicine Institute for Regenerative Medicine. Learn more at www.worldstemcellsummit.com.

About Biostage
Biostage is a biotechnology company developing bioengineered organ implants based on the company's new Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan™ organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

Cellspan implants are currently being advanced and tested in collaborative preclinical studies. Preclinical, large-animal safety studies, conducted in compliance with the FDA Good Laboratory Practice (GLP) regulations, for the Company's Cellspan Esophageal Implant product candidate are ongoing, in support of Biostage's goal of filing an Investigational New Drug (IND) application with the U.S. FDA in the third quarter of 2017. The IND will seek approval to initiate clinical trials for its esophageal implant product candidate in humans.

For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn. 

Forward-Looking Statements:
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology,  which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:


Tom McNaughton

Jenene Thomas

Chief Financial Officer

Jenene Thomas Communications LLC

774-233-7321

(908) 938-1475

tmcnaughton@biostage.com

jtc@jenenethomascommunications.com



Media Contacts:


David Schull or Maggie Beller


Russo Partners LLC


212-845-4271 or 646-942-5631


Email: Maggie.beller@russopartnersllc.com


Logo - http://photos.prnewswire.com/prnh/20160330/349802LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biostage-to-participate-at-the-2016-world-stem-cell-summit-and-regmed-capital-conference-300373301.html

SOURCE Biostage, Inc.

Copyright 2016 PR Newswire

Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Biostage (QB) Charts.
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Biostage (QB) Charts.